Kardiotorakalna in vaskularna kirurgija (pediatrija)
Economic Outcomes
Safety and effects of two red blood cell transfusion strategies in pediatric cardiac surgery patients: a randomized controlled trial. (odpre novo okno)
Vir: Intensive Care Med 2013;39(11):2011-9.
Indeksirano: PubMed 23995984
DOI: 10.1007/s00134-013-3085-7
https://www.ncbi.nlm.nih.gov/pubmed/23995984 (odpre novo okno)
Pediatric red blood cell transfusions increase resource use. (odpre novo okno)
Vir: J Pediatr 2003;142(2):123-7.
Indeksirano: PubMed 12584531
DOI: 10.1067/mpd.2003.14
https://www.ncbi.nlm.nih.gov/pubmed/12584531 (odpre novo okno)
Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. (odpre novo okno)
Vir: Ann Thorac Surg 1998;66(2):535-40; discussion 541.
Indeksirano: PubMed 9725399
https://www.ncbi.nlm.nih.gov/pubmed/9725399 (odpre novo okno)
Comparative analysis of antifibrinolytic medications in pediatric heart surgery. (odpre novo okno)
Vir: J Thorac Cardiovasc Surg 2012;143(3):550-7.
Indeksirano: PubMed 22264414
DOI: 10.1016/j.jtcvs.2011.06.048
https://www.ncbi.nlm.nih.gov/pubmed/22264414 (odpre novo okno)
Economic evaluation of cell salvage in pediatric surgery. (odpre novo okno)
Vir: Paediatr Anaesth 2013;23(11):1027-34.
Indeksirano: PubMed 23952976
DOI: 10.1111/pan.12233
https://www.ncbi.nlm.nih.gov/pubmed/23952976 (odpre novo okno)